蒲地蓝消炎口服液治疗小儿上呼吸道感染meta分析.pdfVIP

蒲地蓝消炎口服液治疗小儿上呼吸道感染 meta 分析 张捷，史宁，李艳蕾，郭宏举，常李荣 （解放军第306 医院药学部 北京 100101 ） 摘要: 目的 系统评价蒲地蓝消炎口服液治疗小儿上呼吸道感染的疗效及安全 性。方法 EMBase 、PubMed 、中国期刊全文数据库（CNKI ）、中国生物医学文 献数据库（CBM ）、中文科技期刊全文数据库（VIP ）、万方科技数据库关于蒲地 蓝消炎口服液治疗小儿上呼吸道感染的随机对照试验（各数据库检索时间均从创 建至 2014 年 3 月），并进行Meta 分析。结果 共纳入 14 篇文献，包括 2035 例患 者。Meta 分析结果显示，试验组有效率优于对照组[RR =1.20 ，95% CI （1.16,1.25）， P ＜0.01] ；退热时间短于对照组[MD =-20.26 ，95% CI （-29.17,-11.35，P ＜0.001] 。 试验组不良反应发生率[OR =1.08 ，95%CI （0.43,2.71 ），P =0.59]与对照组之间差 异无统计学意义。结论 基于现有临床证据，蒲地蓝消炎口服液治疗小儿上呼吸 道感染有效且安全性好。但因纳入研究文献数量较少，研究质量不齐，此结论尚 需更多大样本、高质量临床随机对照试验予以证实。 关键词: 蒲地蓝消炎口服液； 小儿上呼吸道感染； 随机对照试验； meta 分析 A meta-analysis of effects of Pudilan Anti-inflammatory Oral Liquid on child upper respiratory infection ZHANG Jie ，SHI Ning，GUO Hong-ju，LI Yan-lei ，CHANG Li-rong （Department of Pharmacy ,The 306 Hospital of PLA,Beijing China 100101 ） Abstract: Objective To systematically evaluate the efficacy and safety of Pudilan Anti-inflammatory Oral Liquid (PAOL) on children upper respiratory infection (URI). Methods The randomized controlled trials (RCT) of PAOL group for treating URl were retrieved from EMbase, PubMed, CNKI, CBM and VIP (from establish to March 2014), and then a meta-analysis was preformed. Results Fourteen RCTs involving 2035 patients were ultimately identified ．The meta-analysis results showed that the effective rate of PAOL group was superior to that of the control [RR = 1.20, 95% CI (1.16, 1.25), P<0.01]; the defervescence duration of PAOL group was shorter than that of the control [MD = -20.26, 95% CI (-29.17, -11.35, P<0.001]. And there was no significant difference in the incidence rate of adverse reactions between PAOL group and the control [OR =1.08, 95% CI (0.43, 2.71), P =0.59]. Conclusion Based on the present clinical evidence, The meta-analysis results indicate that P